Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Concerning Partial Amendments to the Articles of Incorporation

Subject to approval at the general meeting of shareholders, the Company will transition from a company with an Audit & Supervisory Board to a company with an Audit and Supervisory Committee. At the same time, the Company will state its management philosophy in the Articles of Incorporation and change the maximum number of directors from no more than 10 to no more than 14.

Worth reading
78Important
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
14
Directors (total number; maximum)
Wording
Conditional
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee (subject to approval at the annual general meeting of shareholders scheduled for 24 June 2026)
Number of directorsNo more than 14 directors in total (the number of outside directors is Not disclosed). This comprises no more than 10 directors who are not Audit and Supervisory Committee Members and no more than 4 directors who are Audit and Supervisory Committee Members.
Committee1
Audit and Supervisory Committee . The Nominating Committee and Compensation Committee are 非開示.
Changes this time

Provisions concerning Audit & Supervisory Board Members and the Audit & Supervisory Board will be deleted, and provisions concerning the Audit and Supervisory Committee and Audit and Supervisory Committee Members will be newly established. The management philosophy will be stated in the Articles of Incorporation. The maximum total number of directors will be changed from no more than 10 to no more than 14, comprising no more than 10 directors who are not Audit and Supervisory Committee Members and no more than 4 directors who are Audit and Supervisory Committee Members. Provisions concerning the delegation of important business execution to directors by the Board of Directors will also be newly established.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee (subject to approval at the annual general meeting of shareholders scheduled for 24 June 2026)
Number of directorsNo more than 14 directors in total (the number of outside directors is Not disclosed). This comprises no more than 10 directors who are not Audit and Supervisory Committee Members and no more than 4 directors who are Audit and Supervisory Committee Members.
CommitteeAudit and Supervisory Committee (the proportion of outside members is Not disclosed). The Nominating Committee and Compensation Committee are Not disclosed.
Changes this timeProvisions concerning Audit & Supervisory Board Members and the Audit & Supervisory Board will be deleted, and provisions concerning the Audit and Supervisory Committee and Audit and Supervisory Committee Members will be newly established. The management philosophy will be stated in the Articles of Incorporation. The maximum total number of directors will be changed from no more than 10 to no more than 14, comprising no more than 10 directors who are not Audit and Supervisory Committee Members and no more than 4 directors who are Audit and Supervisory Committee Members. Provisions concerning the delegation of important business execution to directors by the Board of Directors will also be newly established.
Items this document does not state (4)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Stating the management philosophy in the Articles of Incorporation is intended to clarify that the Company's basic principles will not change going forward and to present them clearly to stakeholders. The transition to a company with an Audit and Supervisory Committee is intended to further enhance management transparency and accelerate decision-making.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Partial Amendments to the Articles of Incorporation | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori